Solorank.ai
Login

Cached score snapshot

US.CRL · Charles River Laboratories

110分制 50.5/110；5D動能v2 3/50；排序分 53.5/160 · Incomplete inputs

Back to ranking Open volume snapshot
Ranking score 53.5/160
Main score 50.5/110
5D momentum v2 3/50
Rank #296
Setup grade F 21.5

Score breakdown

避免

Elevated twelvedata

Score and price trend

F 21.5 Elevated risk

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 06-11 07-16 08-18 09-21 10-16 $164.37$269.86$375.35 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.177 · anchors 120 +1.30% -0.64% / +3.77% 65.8% 3.6% Actual outcome pending · 1 / 3 bars observed
30D observation +8.36% -0.85% / +16.67% 72.4% 12.4% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +1.69% -0.48% / +5.06% 67.5% 2.5% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。

2026-06-11 → 2026-10-16 · 89 archived points · 2 Improving turn signal · 4 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 53.5
Display grade 避免
Model version cursor_18_27_news_v2_160
Main score 50.5/110 (避免)
5D momentum v2 3/50 (弱)
Score with momentum v2 53.5/160 (低排序)
Risk level Elevated

Audit trace

Full calculation detail

Calculation detail · 8 sections

Incomplete score

此 snapshot 已計出評分，但以下輸入仍不完整；缺失維度以 0 分處理，請留意 audit 明细。

  • VIX_MISSING: VIX market context is required for market environment scoring

Market inputs

Bar count 60
ma20 288.529
ma50 254.6256
close 288.5
prevClose 293.35
avgVolume20 895865
volumeRatio 0.82
changePercent -1.65

Metrics snapshot

close 288.5
volume 738900
changePercent -1.65

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 50.5/110
Main rating 避免
5D momentum v2 3/50
Score with momentum v2 53.5/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 1.5/5 · 較差
Dimension score 1.5/5
Dimension grade 較差

Sub-items

pbPoints 0.2
pePoints 0
epsPoints 0
roePoints 0
debtPoints 0.4
marginPoints 0
turnoverUsdM 213.1727
volumePoints 0.5
revenuePoints 0
dividendPoints 0
marketCapPoints 0.4

資金流 — 10.8/20 · 較差
Dimension score 10.8/20
Dimension grade 較差

Sub-items

cmfPoints 2.4
mfiPoints 2.4
obvPoints 0.8
vwapPoints 3.2

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.CRL
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 8.4/15 · 較差
Dimension score 8.4/15
Dimension grade 較差

Sub-items

vix

score 0

details

source twelvedata+fred
missing true
vixClose n/a

trend

score 4

details

qqq

ma20 717.5105
ma50 711.085
name QQQ
close 718.96
points 2

spy

ma20 769.053
ma50 756.8572
name SPY
close 770.19
points 2
source twelvedata+fred
atrPct 3.3642
atrPoints 2
cciPoints 2.4
vixPoints 0
marketTrendPoints 4

催化劑 — 2/20 · 較差
Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 8
catalystCount 0
catalystPoints 2

風險管理 — 6.3/10 · 一般
Dimension score 6.3/10
Dimension grade 一般

Sub-items

position

score 1.1

details

atrPct 3.3642
turnoverUsdM 213.1727
liquidityPoints 0.4
volatilityPoints 0.7
rrPoints 1.4

stopLevels

symbol US.CRL
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 269.0886

strength_details

ma_score 1.5
atr_score 1
rsi_score 2
macd_score 1.5
volume_score 1
market_adjustment 1
risk_reward_ratio 1
stop_loss_percent 6.7
take_profit_price 303.2527
target_multiplier 1.6
technical_strength 1.43
take_profit_percent 5.1
positionPoints 1.1
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 6.7284
diversificationPoints 2

技術信號 — 17.5/30 · 較差
Dimension score 17.5/30
Dimension grade 較差

Sub-items

bbPoints 2.4
adxPoints 3
sarPoints 1.2
vcpPoints 2.2
macdPoints 2.4

vcpPayload

vcp_pass false
vcp_score 2.2
vcp_reason 波幅收縮(27.9%→7.8%)；跌縮量(近10日3日)；站上MA50；Ready=Y；Confirm=N

vcp_metrics

up_days 4
vol_ref 919700
down_days 5
vcp_ready true
above_ma50 true
avg_vol_10 839400
avg_vol_20 889545
avg_vol_30 919700
range_pct_10 0.0776
range_pct_20 0.1473
range_pct_30 0.2795
up_expand_ok false
lookback_used 59
near_20d_high true
contraction_ok true
down_shrink_ok true
up_expand_days 0
breakout_20d_ok false
vol_ratio_10_30 0.9127
dist_to_20d_high 0.0488
down_shrink_days 3
breakout_level_20d 303.31
vcp_breakout_confirm false
contraction_ratio_10_30 0.2778
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction true
kdjAdxPoints 0.5
rsiKdjPoints 2.4
volumeWeight 2
maCrossPoints 1.6
shortRsiPoints 0
shortMacdPoints 0.4
volConfirmPoints 0.6
volumePointsTechnical 0.8

情緒分析 — 4/10 · 較差
Dimension score 4/10
Dimension grade 較差

Sub-items

sentiment

score 4

details

source finnhub_news_keyword_model
articleCount 8
negativeHits 0
positiveHits 3
sentimentScoreRaw 0.9

sentimentData

raw {"id":141437887,"url":"https://finnhub.io/api/news?id=570f6ef30a3ed4013ac09e1fb6def884e127b5fc19628370d1cc6637b2a090ce","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.","category":"company","datetime":1788535828,"headline":"Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?"}, {"id":141370262,"url":"https://finnhub.io/api/news?id=7d5ba9371d1930eef6ddb802d9e400ef4e1043175bf691dbcc69f8abd1c72516","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.","category":"company","datetime":1788276600,"headline":"Is This the Right Time to Add CRL Stock to Your Portfolio?"}, {"id":141336294,"url":"https://finnhub.io/api/news?id=ef8df3fc5c0b2610ad30373b2df3764d1ef0c4b3d8b380e888a27cf084572b31","image":"","source":"Fintel","related":"CRL","summary":"","category":"company","datetime":1787909718,"headline":"Charles River Laboratories International (CRL) Price Target Increased by 17.31% to 274.25"}, {"id":141285572,"url":"https://finnhub.io/api/news?id=af0b40c17707cc8a82f48cd3a27bf7abe05443aaf30a2dfc23afab530bdff260","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Earlier this week, Medigen Vaccine Biologics Corp. announced a collaboration with Charles River Laboratories International to characterize and validate the virus seed bank for its next-generation multivalent enterovirus vaccine, with Charles River providing advanced analytical support including Next-Generation Sequencing for key Chemistry, Manufacturing, and Controls activities. The partnership highlights Charles River’s role as a specialized partner for complex biologics testing and...","category":"company","datetime":1787382551,"headline":"Does Charles River (CRL)–Medigen Vaccine Work Sharpen the Case for Its Complex Biologics Edge?"}, {"id":141285581,"url":"https://finnhub.io/api/news?id=77be90221c348c69061a47943095f6b35c8fee65f87bfe82e289e57d88152193","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River Laboratories International (NYSE:CRL) and Medigen Vaccine Biologics announced a collaboration to develop next-generation enterovirus vaccines using advanced analytics and next-generation sequencing. The partnership focuses on using detailed analytical methods to support faster vaccine development timelines and regulatory compliance. Both companies plan to apply novel testing approaches that aim to reduce reliance on animal studies in future vaccine programs. The agreement is...","category":"company","datetime":1787357537,"headline":"Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development?"}, {"id":141282338,"url":"https://finnhub.io/api/news?id=3046de6b1d88ffc7420634e357f1d3676b81f55e4482259675c37a13227475f5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.","category":"company","datetime":1787326620,"headline":"CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?"}, {"id":141202709,"url":"https://finnhub.io/api/news?id=0efb5a2b6093453effc7803e6c9eff82103c331549bf3569fafc3ce671fb0c49","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Organic revenue returned to growth as biopharmaceutical demand strengthened.","category":"company","datetime":1786543990,"headline":"Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript"}, {"id":141175581,"url":"https://finnhub.io/api/news?id=9e605bbf54cfc62e8908998bc6f951c82a7671f2a50aca91f05bc7ef88b5e2e1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.","category":"company","datetime":1786367707,"headline":"International Markets and Charles River (CRL): A Deep Dive for Investors"}
raw_source {"id":141437887,"url":"https://finnhub.io/api/news?id=570f6ef30a3ed4013ac09e1fb6def884e127b5fc19628370d1cc6637b2a090ce","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.","category":"company","datetime":1788535828,"headline":"Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?"}, {"id":141370261,"url":"https://finnhub.io/api/news?id=dccb73f21d41e94b3ecd3b16b380aa2067c9f976406280e57a6c3ae7664bd5a6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"CRAI gains from strong advisory demand, a diverse client base and specialist talent, but rising costs and tight liquidity pose risks.","category":"company","datetime":1788278340,"headline":"Here's Why You Should Hold Charles River Stock in Your Portfolio Now"}, {"id":141370262,"url":"https://finnhub.io/api/news?id=7d5ba9371d1930eef6ddb802d9e400ef4e1043175bf691dbcc69f8abd1c72516","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.","category":"company","datetime":1788276600,"headline":"Is This the Right Time to Add CRL Stock to Your Portfolio?"}, {"id":141336294,"url":"https://finnhub.io/api/news?id=ef8df3fc5c0b2610ad30373b2df3764d1ef0c4b3d8b380e888a27cf084572b31","image":"","source":"Fintel","related":"CRL","summary":"","category":"company","datetime":1787909718,"headline":"Charles River Laboratories International (CRL) Price Target Increased by 17.31% to 274.25"}, {"id":141365553,"url":"https://finnhub.io/api/news?id=fdc5dcdc431b9ef146e761d842d30c65873936be48b831238710ef6a9c07f771","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Opportunities center on non-animal, pharma and regulatory testing, driven by organ-on-chip, organoids, AI biosimulation, genomics and in vitro toxicity platforms.Dublin, Aug. 27, 2026 (GLOBE NEWSWIRE) -- The \"Animal Testing and Non-Animal Alternative Testing Global Market Opportunities and Strategies to 2035\" has been added to ResearchAndMarkets.com's offering. The latest animal testing and non-animal alternative testing market report provides a comprehensive analysis of industry performance fro","category":"company","datetime":1787831520,"headline":"Animal Testing and Non-Animal Alternative Testing Market Outlook 2025-2035 - Featuring Profiles of Charles River Laboratories, Labcorp, and Eurofins Scientific"}, {"id":141365554,"url":"https://finnhub.io/api/news?id=9b4143fb26738fb4ce760aa104946f153b883c1808ce5fea5f547950c7d60d69","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River Laboratories has significantly outperformed the market, while strong guidance and a bullish analyst outlook support continued optimism.","category":"company","datetime":1787751811,"headline":"Is Wall Street Bullish or Bearish on Charles River Laboratories Stock?"}, {"id":141324273,"url":"https://finnhub.io/api/news?id=03721ff268f5dbbeade78dfd1e473153bf81c7da1a58b90d820bc733d942d886","image":"https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536","source":"Benzinga","related":"CRL","summary":"Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.75% on an annualized basis producing an average annual return of 15.76%. Currently, Charles River has a market capitalization of $15.22","category":"company","datetime":1787675434,"headline":"Here's How Much $100 Invested In Charles River 15 Years Ago Would Be Worth Today"}, {"id":141365555,"url":"https://finnhub.io/api/news?id=bb316e03900c98af836f471c4cf8f628d54928ccd4e2251213ea8fb7f392281b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Here is how Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.","category":"company","datetime":1787668803,"headline":"Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?"}, {"id":141363104,"url":"https://finnhub.io/api/news?id=6f5f1c3e39904371e861a27af556e7dccd9d7f4859716741bd9eb776c40e458f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.","category":"company","datetime":1787660324,"headline":"3 Inflated Stocks We Approach with Caution"}, {"id":141313731,"url":"https://finnhub.io/api/news?id=515bc7cdf58d72a1174672bd595355a9f13d453d64545924216c27831956087e","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"CRL","summary":"Ariel Investments' 13F portfolio rose to $10.03B in Q2 2026, with 27 core positions, each over 2% of assets. Read more on the portfolio here.","category":"company","datetime":1787608034,"headline":"Tracking John Rogers' Ariel Investments Portfolio - Q2 2026 Update"}, {"id":141285572,"url":"https://finnhub.io/api/news?id=af0b40c17707cc8a82f48cd3a27bf7abe05443aaf30a2dfc23afab530bdff260","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Earlier this week, Medigen Vaccine Biologics Corp. announced a collaboration with Charles River Laboratories International to characterize and validate the virus seed bank for its next-generation multivalent enterovirus vaccine, with Charles River providing advanced analytical support including Next-Generation Sequencing for key Chemistry, Manufacturing, and Controls activities. The partnership highlights Charles River’s role as a specialized partner for complex biologics testing and...","category":"company","datetime":1787382551,"headline":"Does Charles River (CRL)–Medigen Vaccine Work Sharpen the Case for Its Complex Biologics Edge?"}, {"id":141285581,"url":"https://finnhub.io/api/news?id=77be90221c348c69061a47943095f6b35c8fee65f87bfe82e289e57d88152193","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River Laboratories International (NYSE:CRL) and Medigen Vaccine Biologics announced a collaboration to develop next-generation enterovirus vaccines using advanced analytics and next-generation sequencing. The partnership focuses on using detailed analytical methods to support faster vaccine development timelines and regulatory compliance. Both companies plan to apply novel testing approaches that aim to reduce reliance on animal studies in future vaccine programs. The agreement is...","category":"company","datetime":1787357537,"headline":"Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development?"}, {"id":141282338,"url":"https://finnhub.io/api/news?id=3046de6b1d88ffc7420634e357f1d3676b81f55e4482259675c37a13227475f5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.","category":"company","datetime":1787326620,"headline":"CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?"}, {"id":141285574,"url":"https://finnhub.io/api/news?id=d55e1da5409b429b35a7e8668915c0b4b965ccb81c477b45942733fffe190b30","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Investors need to pay close attention to CRL stock based on the movements in the options market lately.","category":"company","datetime":1787326140,"headline":"Are Options Traders Betting on a Big Move in Charles River Stock?"}, {"id":141285575,"url":"https://finnhub.io/api/news?id=1e12ffa39729ca80a074f28e25ebc90e0f13ac69e39100a037ee9c241e4da6e5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"CRL's shares have surged 88.6% in a year as DSA returns to organic growth, bookings climb and new testing initiatives broaden its strategy.","category":"company","datetime":1787323800,"headline":"Charles River Gains 88.6% in a Year: What's Driving the Rally?"}, {"id":141285576,"url":"https://finnhub.io/api/news?id=b2b5eccf3c195c8eeeeab121ada79465da1aee4e17871e56b32bb091bbe98e1b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"WILMINGTON, Mass., August 20, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) and Medigen Vaccine Biologics Corp. (MVC) collaborate on the characterization and validation of the virus seed bank for MVC's next-generation multivalent enterovirus vaccine. Charles River will leverage its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support critical steps of Chemistry, Manufacturing, and Controls (CMC) activities for MVC’s next-generation multivalent","category":"company","datetime":1787230800,"headline":"Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing"}, {"id":141262451,"url":"https://finnhub.io/api/news?id=a978100f9c3dbfb785d08bbc780cce434527e9bc36bd7a900f59c0d83731d12b","image":"","source":"Benzinga","related":"CRL","summary":"Collaboration leverages NGS technologies to accelerate high-quality vaccine development, support global regulatory readiness, and help reduce animal testingCharles River Laboratories International, Inc. (NYSE:CRL) and","category":"company","datetime":1787213070,"headline":"Charles River Laboratories And Medigen Vaccine Biologics Collaborate On Characterization And Validation Of Virus Seed Bank For MVC's Next-Gen Multivalent Enterovirus Vaccine"}, {"id":141278737,"url":"https://finnhub.io/api/news?id=67621dd00d7b4422294b7c05c38a9ef3f25ba0e393e2e079e5179b2aacf01c1b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Opportunities span AI-driven protein design and structure prediction, precision therapeutics, engineered biologics and vaccines, synthetic biology, novel enzymes, high-throughput screening, and advanced computational modeling, with Asia-Pacific offering expansion potential. Protein Design and Engineering Market Protein Design and Engineering Market Dublin, Aug. 19, 2026 (GLOBE NEWSWIRE) -- The \"Protein Design and Engineering Market Global Report 2026\" has been added to ResearchAndMarkets.com's o","category":"company","datetime":1787153280,"headline":"Protein Design & Engineering Market Global Report 2026: Evaluating AI Platforms, Rational Design, Directed Evolution, and Strategies of Lonza, Thermo Fisher, GenScript, and Charles River"}, {"id":141285582,"url":"https://finnhub.io/api/news?id=f2ffc4928df30f512c782bc6b60e29e580fed74bfd7e67ea7c362ea378082700","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.","category":"company","datetime":1786892220,"headline":"1 Mid-Cap Stock with Exciting Potential and 2 Facing Challenges"}, {"id":141227357,"url":"https://finnhub.io/api/news?id=2c836453d3e6f0af9a9702b3e6d516f9c1819c14ee6ffb3301e0bfa804000082","image":"https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536","source":"Benzinga","related":"CRL","summary":"Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.07% on an annualized basis producing an average annual return of 15.79%. Currently, Charles River has a market capitalization of $14.32","category":"company","datetime":1786731338,"headline":"If You Invested $100 In Charles River Stock 15 Years Ago, You Would Have This Much Today"}, {"id":141215096,"url":"https://finnhub.io/api/news?id=7b5a09f8c6c584297399c2fb76a48bf64775c609a21dbfb5f5ace62915a2d7ec","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River Laboratories’ second quarter results were shaped by recovering biopharmaceutical demand and the impact of portfolio streamlining. Management highlighted that the rebound was most evident in the Discovery and Safety Assessment (DSA) segment, where net book-to-bill reached a four-year high and organic revenue growth turned positive for the first time since 2023. CEO Birgit Girshick pointed to an uptick in proposal activity and improved funding for small and midsize biotech clients as","category":"company","datetime":1786687500,"headline":"5 Insightful Analyst Questions From Charles River Laboratories’s Q2 Earnings Call"}, {"id":141202709,"url":"https://finnhub.io/api/news?id=0efb5a2b6093453effc7803e6c9eff82103c331549bf3569fafc3ce671fb0c49","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Organic revenue returned to growth as biopharmaceutical demand strengthened.","category":"company","datetime":1786543990,"headline":"Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript"}, {"id":141202710,"url":"https://finnhub.io/api/news?id=a7a24f83c22499d705ad49a15fac3e9070b500eb535ee5dccbfaa5d3e0c08fba","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"CRAI's 20% three-month gain is backed by broader demand, a stronger project pipeline and higher fiscal 2026 revenue guidance, but costs remain a drag.","category":"company","datetime":1786455240,"headline":"CRAI Jumps 20% in 3 Months as Demand Broadens Across Key Practices"}, {"id":141175581,"url":"https://finnhub.io/api/news?id=9e605bbf54cfc62e8908998bc6f951c82a7671f2a50aca91f05bc7ef88b5e2e1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.","category":"company","datetime":1786367707,"headline":"International Markets and Charles River (CRL): A Deep Dive for Investors"}, {"id":141175911,"url":"https://finnhub.io/api/news?id=8a7f50cf2d7987439b6e1aabb07e3274bbab3b848cd38df052cf6ccd9adcc09b","image":"","source":"Benzinga","related":"CRL","summary":"TD Cowen analyst Charles Rhyee maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $235 to $300.","category":"company","datetime":1786361246,"headline":"TD Cowen Maintains Buy on Charles River, Raises Price Target to $300"}
data_source finnhub_news_keyword_model
article_count 8
negative_hits 0
positive_hits 3
recomputed_at_score true
sentiment_score_raw 0.9
source_article_count 25
discarded_article_count 17
sentimentPoints 4

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 1.5 5/110 30% 1.5
資金流 10.8 20/110 54% 10.8
市場環境 8.4 15/110 56% 8.4
催化劑 2 20/110 10% 2
風險管理 6.3 10/110 63% 6.3
技術信號 17.5 30/110 58.33% 17.5
情緒分析 4 10/110 40% 4

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 3/50
ret_5d -0.0103
max_score 50
max_total 50
raw_total 3
vcp_bonus 0
vol_ratio 0.8306
ret_points 0
vol_points 0
range_ratio 0.68
volat_points 0
day_range_pct 0.022
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 3
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Elevated
reason risk management score >= 5/10

position

score 1.1

details

atrPct 3.3642
turnoverUsdM 213.1727
liquidityPoints 0.4
volatilityPoints 0.7
rrPoints 1.4

stopLevels

symbol US.CRL
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 269.0886

strength_details

ma_score 1.5
atr_score 1
rsi_score 2
macd_score 1.5
volume_score 1
market_adjustment 1
risk_reward_ratio 1
stop_loss_percent 6.7
take_profit_price 303.2527
target_multiplier 1.6
technical_strength 1.43
take_profit_percent 5.1
positionPoints 1.1
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 6.7284
diversificationPoints 2

Calculation audit log

基本面分析總分: 1.5/5分
資金流分析總分: 10.8/20分
市場環境分析總分: 8.4/15分
催化劑分析: 2/20分
風險管理總分: 6.3/10分
技術信號分析總分: 17.5/30分
情緒分析: 4/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 92.86
atr
atr 9.7057
rule ATR / current price; lower volatility scores higher
score 4
atr_pct 3.36
cci
rule Cursor_18.24 CCI bands
level 平衡
score 6
value 6.02
cmf
rule Cursor_18.24 CMF bands
level 輕微流入
score 6
value 0.1373
kdj
d 49.56
j 29.62
k 42.91
rule Cursor_18.24 K/D cross
score 0
signal 死叉
mfi
rule Cursor_18.24 MFI bands
level 平衡
score 6
value 57.23
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 2
trend 資金流出
value 8620600
recentSlope -315110
previousSlope 441470
rsi
value 51.51
sar
rule Cursor_18.24 Parabolic SAR
score 4
trend 下降
value 298.6662
position SAR喺價上
distancePct 3.52
previousTrend 下降
ma50
value 254.6256
macd
macd 11.1775
trend 中性偏多
signal 13.8086
histogram -2.6311
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 8
value 287.8113
position 連續3日>VWAP
consecutiveAbove 3
volume
rule Cursor_18.24 volume ratio
level 無力
ratio 0.82
score 4
avgVolume 895865
currentVolume 738900
derived
ma20 288.529
ma50 254.6256
prevClose 293.35
avgVolume10 824540
avgVolume20 895865
changePercent -1.65
avgVolumeForScore 895865
ma_cross
ma20 288.529
ma50 254.6256
rule Cursor_18.24 MA20/MA50 cross
cross 多頭
score 4
prevMa20 287.4785
prevMa50 253.1098
spreadPct 13.32
isVolumeBreakout false
bollinger
lower 275.6178
upper 301.4402
position 中間
rsi_short
value 36.79
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 0.82

Raw calculation JSON

 
{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.1,
      "details": {
        "atrPct": 3.36419410745234,
        "turnoverUsdM": 213.17265,
        "liquidityPoints": 0.4,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.CRL",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 269.0886,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 2,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 6.7,
      "take_profit_price": 303.2527,
      "target_multiplier": 1.6,
      "technical_strength": 1.43,
      "take_profit_percent": 5.1
    },
    "positionPoints": 1.1,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 6.72838821490468,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 53.5,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 50.5,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 3
  },
  "market": {
    "ma20": 288.529,
    "ma50": 254.6256,
    "close": 288.5,
    "prevClose": 293.35,
    "avgVolume20": 895865,
    "volumeRatio": 0.82,
    "changePercent": -1.65
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 3,
    "details": {
      "ret_5d": -0.010291595197255532,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 3,
      "vcp_bonus": 0,
      "vol_ratio": 0.8306493769286545,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.6799818131870774,
      "volat_points": 0,
      "day_range_pct": 0.022010398613518275,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 53.5,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 1.5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 30,
        "contribution": 1.5
      },
      {
        "raw": 10.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 54,
        "contribution": 10.8
      },
      {
        "raw": 8.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 56,
        "contribution": 8.4
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.3,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 63,
        "contribution": 6.3
      },
      {
        "raw": 17.5,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 58.33,
        "contribution": 17.5
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 50.5,
    "details": [
      "基本面分析總分: 1.5/5分",
      "資金流分析總分: 10.8/20分",
      "市場環境分析總分: 8.4/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.3/10分",
      "技術信號分析總分: 17.5/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 1.5,
      "資金流": 10.8,
      "市場環境": 8.4,
      "情緒分析": 4,
      "技術信號": 17.5,
      "風險管理": 6.3
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 213.17265,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.4
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 2.4,
          "obvPoints": 0.8,
          "vwapPoints": 3.2,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.CRL",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 4,
            "details": {
              "qqq": {
                "ma20": 717.5105010500001,
                "ma50": 711.0850000400001,
                "name": "QQQ",
                "close": 718.96002,
                "points": 2
              },
              "spy": {
                "ma20": 769.0529934000002,
                "ma50": 756.85720062,
                "name": "SPY",
                "close": 770.19,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.36419410745234,
          "atrPoints": 2,
          "cciPoints": 2.4,
          "vixPoints": 0,
          "marketTrendPoints": 4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 3,
              "sentimentScoreRaw": 0.9
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141437887,
                "url": "https://finnhub.io/api/news?id=570f6ef30a3ed4013ac09e1fb6def884e127b5fc19628370d1cc6637b2a090ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788535828,
                "headline": "Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 141370262,
                "url": "https://finnhub.io/api/news?id=7d5ba9371d1930eef6ddb802d9e400ef4e1043175bf691dbcc69f8abd1c72516",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.",
                "category": "company",
                "datetime": 1788276600,
                "headline": "Is This the Right Time to Add CRL Stock to Your Portfolio?"
              },
              {
                "id": 141336294,
                "url": "https://finnhub.io/api/news?id=ef8df3fc5c0b2610ad30373b2df3764d1ef0c4b3d8b380e888a27cf084572b31",
                "image": "",
                "source": "Fintel",
                "related": "CRL",
                "summary": "",
                "category": "company",
                "datetime": 1787909718,
                "headline": "Charles River Laboratories International (CRL) Price Target Increased by 17.31% to 274.25"
              },
              {
                "id": 141285572,
                "url": "https://finnhub.io/api/news?id=af0b40c17707cc8a82f48cd3a27bf7abe05443aaf30a2dfc23afab530bdff260",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Earlier this week, Medigen Vaccine Biologics Corp. announced a collaboration with Charles River Laboratories International to characterize and validate the virus seed bank for its next-generation multivalent enterovirus vaccine, with Charles River providing advanced analytical support including Next-Generation Sequencing for key Chemistry, Manufacturing, and Controls activities. The partnership highlights Charles River’s role as a specialized partner for complex biologics testing and...",
                "category": "company",
                "datetime": 1787382551,
                "headline": "Does Charles River (CRL)–Medigen Vaccine Work Sharpen the Case for Its Complex Biologics Edge?"
              },
              {
                "id": 141285581,
                "url": "https://finnhub.io/api/news?id=77be90221c348c69061a47943095f6b35c8fee65f87bfe82e289e57d88152193",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International (NYSE:CRL) and Medigen Vaccine Biologics announced a collaboration to develop next-generation enterovirus vaccines using advanced analytics and next-generation sequencing. The partnership focuses on using detailed analytical methods to support faster vaccine development timelines and regulatory compliance. Both companies plan to apply novel testing approaches that aim to reduce reliance on animal studies in future vaccine programs. The agreement is...",
                "category": "company",
                "datetime": 1787357537,
                "headline": "Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development?"
              },
              {
                "id": 141282338,
                "url": "https://finnhub.io/api/news?id=3046de6b1d88ffc7420634e357f1d3676b81f55e4482259675c37a13227475f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.",
                "category": "company",
                "datetime": 1787326620,
                "headline": "CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?"
              },
              {
                "id": 141202709,
                "url": "https://finnhub.io/api/news?id=0efb5a2b6093453effc7803e6c9eff82103c331549bf3569fafc3ce671fb0c49",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Organic revenue returned to growth as biopharmaceutical demand strengthened.",
                "category": "company",
                "datetime": 1786543990,
                "headline": "Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141175581,
                "url": "https://finnhub.io/api/news?id=9e605bbf54cfc62e8908998bc6f951c82a7671f2a50aca91f05bc7ef88b5e2e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.",
                "category": "company",
                "datetime": 1786367707,
                "headline": "International Markets and Charles River (CRL): A Deep Dive for Investors"
              }
            ],
            "raw_source": [
              {
                "id": 141437887,
                "url": "https://finnhub.io/api/news?id=570f6ef30a3ed4013ac09e1fb6def884e127b5fc19628370d1cc6637b2a090ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788535828,
                "headline": "Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 141370261,
                "url": "https://finnhub.io/api/news?id=dccb73f21d41e94b3ecd3b16b380aa2067c9f976406280e57a6c3ae7664bd5a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "CRAI gains from strong advisory demand, a diverse client base and specialist talent, but rising costs and tight liquidity pose risks.",
                "category": "company",
                "datetime": 1788278340,
                "headline": "Here's Why You Should Hold Charles River Stock in Your Portfolio Now"
              },
              {
                "id": 141370262,
                "url": "https://finnhub.io/api/news?id=7d5ba9371d1930eef6ddb802d9e400ef4e1043175bf691dbcc69f8abd1c72516",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.",
                "category": "company",
                "datetime": 1788276600,
                "headline": "Is This the Right Time to Add CRL Stock to Your Portfolio?"
              },
              {
                "id": 141336294,
                "url": "https://finnhub.io/api/news?id=ef8df3fc5c0b2610ad30373b2df3764d1ef0c4b3d8b380e888a27cf084572b31",
                "image": "",
                "source": "Fintel",
                "related": "CRL",
                "summary": "",
                "category": "company",
                "datetime": 1787909718,
                "headline": "Charles River Laboratories International (CRL) Price Target Increased by 17.31% to 274.25"
              },
              {
                "id": 141365553,
                "url": "https://finnhub.io/api/news?id=fdc5dcdc431b9ef146e761d842d30c65873936be48b831238710ef6a9c07f771",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Opportunities center on non-animal, pharma and regulatory testing, driven by organ-on-chip, organoids, AI biosimulation, genomics and in vitro toxicity platforms.Dublin, Aug. 27, 2026 (GLOBE NEWSWIRE) -- The \"Animal Testing and Non-Animal Alternative Testing Global Market Opportunities and Strategies to 2035\" has been added to ResearchAndMarkets.com's offering. The latest animal testing and non-animal alternative testing market report provides a comprehensive analysis of industry performance fro",
                "category": "company",
                "datetime": 1787831520,
                "headline": "Animal Testing and Non-Animal Alternative Testing Market Outlook 2025-2035 - Featuring Profiles of Charles River Laboratories, Labcorp, and Eurofins Scientific"
              },
              {
                "id": 141365554,
                "url": "https://finnhub.io/api/news?id=9b4143fb26738fb4ce760aa104946f153b883c1808ce5fea5f547950c7d60d69",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories has significantly outperformed the market, while strong guidance and a bullish analyst outlook support continued optimism.",
                "category": "company",
                "datetime": 1787751811,
                "headline": "Is Wall Street Bullish or Bearish on Charles River Laboratories Stock?"
              },
              {
                "id": 141324273,
                "url": "https://finnhub.io/api/news?id=03721ff268f5dbbeade78dfd1e473153bf81c7da1a58b90d820bc733d942d886",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.75% on an annualized basis producing an average annual return of 15.76%. Currently, Charles River has a market capitalization of $15.22",
                "category": "company",
                "datetime": 1787675434,
                "headline": "Here's How Much $100 Invested In Charles River 15 Years Ago Would Be Worth Today"
              },
              {
                "id": 141365555,
                "url": "https://finnhub.io/api/news?id=bb316e03900c98af836f471c4cf8f628d54928ccd4e2251213ea8fb7f392281b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Here is how Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.",
                "category": "company",
                "datetime": 1787668803,
                "headline": "Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?"
              },
              {
                "id": 141363104,
                "url": "https://finnhub.io/api/news?id=6f5f1c3e39904371e861a27af556e7dccd9d7f4859716741bd9eb776c40e458f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.",
                "category": "company",
                "datetime": 1787660324,
                "headline": "3 Inflated  Stocks We Approach with Caution"
              },
              {
                "id": 141313731,
                "url": "https://finnhub.io/api/news?id=515bc7cdf58d72a1174672bd595355a9f13d453d64545924216c27831956087e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "Ariel Investments' 13F portfolio rose to $10.03B in Q2 2026, with 27 core positions, each over 2% of assets. Read more on the portfolio here.",
                "category": "company",
                "datetime": 1787608034,
                "headline": "Tracking John Rogers' Ariel Investments Portfolio - Q2 2026 Update"
              },
              {
                "id": 141285572,
                "url": "https://finnhub.io/api/news?id=af0b40c17707cc8a82f48cd3a27bf7abe05443aaf30a2dfc23afab530bdff260",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Earlier this week, Medigen Vaccine Biologics Corp. announced a collaboration with Charles River Laboratories International to characterize and validate the virus seed bank for its next-generation multivalent enterovirus vaccine, with Charles River providing advanced analytical support including Next-Generation Sequencing for key Chemistry, Manufacturing, and Controls activities. The partnership highlights Charles River’s role as a specialized partner for complex biologics testing and...",
                "category": "company",
                "datetime": 1787382551,
                "headline": "Does Charles River (CRL)–Medigen Vaccine Work Sharpen the Case for Its Complex Biologics Edge?"
              },
              {
                "id": 141285581,
                "url": "https://finnhub.io/api/news?id=77be90221c348c69061a47943095f6b35c8fee65f87bfe82e289e57d88152193",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International (NYSE:CRL) and Medigen Vaccine Biologics announced a collaboration to develop next-generation enterovirus vaccines using advanced analytics and next-generation sequencing. The partnership focuses on using detailed analytical methods to support faster vaccine development timelines and regulatory compliance. Both companies plan to apply novel testing approaches that aim to reduce reliance on animal studies in future vaccine programs. The agreement is...",
                "category": "company",
                "datetime": 1787357537,
                "headline": "Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development?"
              },
              {
                "id": 141282338,
                "url": "https://finnhub.io/api/news?id=3046de6b1d88ffc7420634e357f1d3676b81f55e4482259675c37a13227475f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.",
                "category": "company",
                "datetime": 1787326620,
                "headline": "CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?"
              },
              {
                "id": 141285574,
                "url": "https://finnhub.io/api/news?id=d55e1da5409b429b35a7e8668915c0b4b965ccb81c477b45942733fffe190b30",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Investors need to pay close attention to CRL stock based on the movements in the options market lately.",
                "category": "company",
                "datetime": 1787326140,
                "headline": "Are Options Traders Betting on a Big Move in Charles River Stock?"
              },
              {
                "id": 141285575,
                "url": "https://finnhub.io/api/news?id=1e12ffa39729ca80a074f28e25ebc90e0f13ac69e39100a037ee9c241e4da6e5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "CRL's shares have surged 88.6% in a year as DSA returns to organic growth, bookings climb and new testing initiatives broaden its strategy.",
                "category": "company",
                "datetime": 1787323800,
                "headline": "Charles River Gains 88.6% in a Year: What's Driving the Rally?"
              },
              {
                "id": 141285576,
                "url": "https://finnhub.io/api/news?id=b2b5eccf3c195c8eeeeab121ada79465da1aee4e17871e56b32bb091bbe98e1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., August 20, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) and Medigen Vaccine Biologics Corp. (MVC) collaborate on the characterization and validation of the virus seed bank for MVC's next-generation multivalent enterovirus vaccine. Charles River will leverage its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support critical steps of Chemistry, Manufacturing, and Controls (CMC) activities for MVC’s next-generation multivalent",
                "category": "company",
                "datetime": 1787230800,
                "headline": "Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing"
              },
              {
                "id": 141262451,
                "url": "https://finnhub.io/api/news?id=a978100f9c3dbfb785d08bbc780cce434527e9bc36bd7a900f59c0d83731d12b",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Collaboration leverages NGS technologies to accelerate high-quality vaccine development, support global regulatory readiness, and help reduce animal testingCharles River Laboratories International, Inc. (NYSE:CRL) and",
                "category": "company",
                "datetime": 1787213070,
                "headline": "Charles River Laboratories And Medigen Vaccine Biologics Collaborate On Characterization And Validation Of Virus Seed Bank For MVC's Next-Gen Multivalent Enterovirus Vaccine"
              },
              {
                "id": 141278737,
                "url": "https://finnhub.io/api/news?id=67621dd00d7b4422294b7c05c38a9ef3f25ba0e393e2e079e5179b2aacf01c1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Opportunities span AI-driven protein design and structure prediction, precision therapeutics, engineered biologics and vaccines, synthetic biology, novel enzymes, high-throughput screening, and advanced computational modeling, with Asia-Pacific offering expansion potential. Protein Design and Engineering Market Protein Design and Engineering Market Dublin, Aug. 19, 2026 (GLOBE NEWSWIRE) -- The \"Protein Design and Engineering Market Global Report 2026\" has been added to ResearchAndMarkets.com's o",
                "category": "company",
                "datetime": 1787153280,
                "headline": "Protein Design & Engineering Market Global Report 2026: Evaluating AI Platforms, Rational Design, Directed Evolution, and Strategies of Lonza, Thermo Fisher, GenScript, and Charles River"
              },
              {
                "id": 141285582,
                "url": "https://finnhub.io/api/news?id=f2ffc4928df30f512c782bc6b60e29e580fed74bfd7e67ea7c362ea378082700",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.",
                "category": "company",
                "datetime": 1786892220,
                "headline": "1 Mid-Cap Stock with Exciting Potential and 2 Facing Challenges"
              },
              {
                "id": 141227357,
                "url": "https://finnhub.io/api/news?id=2c836453d3e6f0af9a9702b3e6d516f9c1819c14ee6ffb3301e0bfa804000082",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.07% on an annualized basis producing an average annual return of 15.79%. Currently, Charles River has a market capitalization of $14.32",
                "category": "company",
                "datetime": 1786731338,
                "headline": "If You Invested $100 In Charles River Stock 15 Years Ago, You Would Have This Much Today"
              },
              {
                "id": 141215096,
                "url": "https://finnhub.io/api/news?id=7b5a09f8c6c584297399c2fb76a48bf64775c609a21dbfb5f5ace62915a2d7ec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories’ second quarter results were shaped by recovering biopharmaceutical demand and the impact of portfolio streamlining. Management highlighted that the rebound was most evident in the Discovery and Safety Assessment (DSA) segment, where net book-to-bill reached a four-year high and organic revenue growth turned positive for the first time since 2023. CEO Birgit Girshick pointed to an uptick in proposal activity and improved funding for small and midsize biotech clients as",
                "category": "company",
                "datetime": 1786687500,
                "headline": "5 Insightful Analyst Questions From Charles River Laboratories’s Q2 Earnings Call"
              },
              {
                "id": 141202709,
                "url": "https://finnhub.io/api/news?id=0efb5a2b6093453effc7803e6c9eff82103c331549bf3569fafc3ce671fb0c49",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Organic revenue returned to growth as biopharmaceutical demand strengthened.",
                "category": "company",
                "datetime": 1786543990,
                "headline": "Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141202710,
                "url": "https://finnhub.io/api/news?id=a7a24f83c22499d705ad49a15fac3e9070b500eb535ee5dccbfaa5d3e0c08fba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "CRAI's 20% three-month gain is backed by broader demand, a stronger project pipeline and higher fiscal 2026 revenue guidance, but costs remain a drag.",
                "category": "company",
                "datetime": 1786455240,
                "headline": "CRAI Jumps 20% in 3 Months as Demand Broadens Across Key Practices"
              },
              {
                "id": 141175581,
                "url": "https://finnhub.io/api/news?id=9e605bbf54cfc62e8908998bc6f951c82a7671f2a50aca91f05bc7ef88b5e2e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.",
                "category": "company",
                "datetime": 1786367707,
                "headline": "International Markets and Charles River (CRL): A Deep Dive for Investors"
              },
              {
                "id": 141175911,
                "url": "https://finnhub.io/api/news?id=8a7f50cf2d7987439b6e1aabb07e3274bbab3b848cd38df052cf6ccd9adcc09b",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "TD Cowen  analyst Charles Rhyee   maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $235 to $300.",
                "category": "company",
                "datetime": 1786361246,
                "headline": "TD Cowen Maintains Buy on Charles River, Raises Price Target to $300"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 3,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.9,
            "source_article_count": 25,
            "discarded_article_count": 17
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 17.5,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.2,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.2,
            "vcp_reason": "波幅收縮(27.9%→7.8%)；跌縮量(近10日3日)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 919700,
              "down_days": 5,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 839400,
              "avg_vol_20": 889545,
              "avg_vol_30": 919700,
              "range_pct_10": 0.07764298093587514,
              "range_pct_20": 0.14727899480069317,
              "range_pct_30": 0.27948010398613515,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9126889203000979,
              "dist_to_20d_high": 0.048827931818931136,
              "down_shrink_days": 3,
              "breakout_level_20d": 303.31,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.2778121942438055
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.1,
            "details": {
              "atrPct": 3.36419410745234,
              "turnoverUsdM": 213.17265,
              "liquidityPoints": 0.4,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.CRL",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 269.0886,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 2,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 6.7,
            "take_profit_price": 303.2527,
            "target_multiplier": 1.6,
            "technical_strength": 1.43,
            "take_profit_percent": 5.1
          },
          "positionPoints": 1.1,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 6.72838821490468,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.CRL",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 9.7057,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.36
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "平衡",
      "score": 6,
      "value": 6.02
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.1373
    },
    "kdj": {
      "d": 49.56,
      "j": 29.62,
      "k": 42.91,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 57.23
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 8620600,
      "recentSlope": -315110,
      "previousSlope": 441470
    },
    "rsi": 51.51,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 298.6662,
      "position": "SAR喺價上",
      "distancePct": 3.52,
      "previousTrend": "下降"
    },
    "ma50": 254.6256,
    "macd": {
      "macd": 11.177511491823509,
      "trend": "中性偏多",
      "signal": 13.808623365473546,
      "histogram": -2.6311118736500365
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 8,
      "value": 287.8113,
      "position": "連續3日>VWAP",
      "consecutiveAbove": 3
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.82,
      "score": 4,
      "avgVolume": 895865,
      "currentVolume": 738900
    },
    "derived": {
      "ma20": 288.529,
      "ma50": 254.6256,
      "prevClose": 293.35,
      "avgVolume10": 824540,
      "avgVolume20": 895865,
      "changePercent": -1.65,
      "avgVolumeForScore": 895865
    },
    "ma_cross": {
      "ma20": 288.529,
      "ma50": 254.6256,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 287.4785,
      "prevMa50": 253.1098,
      "spreadPct": 13.32,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 275.6178,
      "upper": 301.4402,
      "position": "中間"
    },
    "rsi_short": 36.79,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.82
    }
  }
}

Raw metrics JSON

 
{
  "close": 288.5,
  "volume": 738900,
  "changePercent": -1.65
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.